secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060238
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics Q3 net loss narrows to $11.6M; cash $349.7M supports operations through 2027
--------------------------------------------------------------------------------

- Net loss $11.6M vs $16.7M YoY; R&D expenses $11.9M, G&A $6.4M.
- Cash and short-term investments $349.7M, up from $327.0M at year-end 2022, expected to fund operations through 2027.
- Enrollment ongoing for JANX007 (PSMA-TRACTr) in prostate cancer and JANX008 (EGFR-TRACTr) in solid tumors; update expected in 2024.
- IND-enabling studies completed for JANX009 (PD-L1xCD28 TRACIr); TROP2-TRACTr candidate identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023060238/0000950170-23-060238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023060238/janx-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer